The Clinical Core of the Program Project Grant will perform the cognitive and clinical assessments for all subjects taking part in the Program Project Grant (PPG). The Clinical Core will recruit and assess subjects with Mild Cognitive Impairment (MCI) and will continue to follow existing Normal Healthy Control Subjects. The Core will review the study protocols with potential subjects and obtain full informed consent, perform cognitive, clinical and neurological assessments necessary for the protocol. Follow-up appointments and ongoing telephone contact with subjects will be coordinated through the Core. The Clinical Core will coordinate with the ADRC and the Aging Study to ensure accurate and timely transfer of clinical information, cognitive scores and other data relevant to the PPG dataset and subsequently to the Imaging, Methodology and Statistics (IMS) Core for data analysis and correlation with PIB PET and imaging data. The PPG Coordinating Committee comprising the Pis of the Clinical Core, Administrative Core, IMS Core, and Pis and Co-Is of the 3 projects and the PPG Administrator will oversee the Clinical Core. All of the Investigators in the Core and all of the individuals with whom they interact to achieve the aims of this Core have worked together for many years, adding to the assurance that the proposed work will be carried out appropriately.
Accurately diagnosed subjects, evaluated and followed longitudinally by skilled clinicians, is the most efficient and practical method of advancing cutting-edge PIB PET research. An experienced staff skilled in eliciting the cooperation of patients and families for PPG projects is a critical element of a well functioning PPG.
|Hu, Ziheng; Wang, Lirong; Ma, Shifan et al. (2018) Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease. Alzheimers Dement (N Y) 4:542-555|
|Zhao, Yujing; Tudorascu, Dana L; Lopez, Oscar L et al. (2018) Amyloid ? Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia. JAMA Neurol 75:88-96|
|Jansen, Willemijn J; Ossenkoppele, Rik; Tijms, Betty M et al. (2018) Association of Cerebral Amyloid-? Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry 75:84-95|
|Wilckens, Kristine A; Tudorascu, Dana L; Snitz, Beth E et al. (2018) Sleep moderates the relationship between amyloid beta and memory recall. Neurobiol Aging 71:142-148|
|Minhas, Davneet S; Price, Julie C; Laymon, Charles M et al. (2018) Impact of partial volume correction on the regional correspondence between in vivo [C-11]PiB PET and postmortem measures of A? load. Neuroimage Clin 19:182-189|
|Yan, Qi; Nho, Kwangsik; Del-Aguila, Jorge L et al. (2018) Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. Mol Psychiatry :|
|La Joie, Renaud; Ayakta, Nagehan; Seeley, William W et al. (2018) Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimers Dement :|
|Cohen, Ann D; McDade, Eric; Christian, Brad et al. (2018) Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition. Alzheimers Dement 14:743-750|
|Marquié, Marta; Normandin, Marc D; Meltzer, Avery C et al. (2017) Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies. Ann Neurol 81:117-128|
|Mi, Zhiping; Abrahamson, Eric E; Ryu, Angela Y et al. (2017) Loss of precuneus dendritic spines immunopositive for spinophilin is related to cognitive impairment in early Alzheimer's disease. Neurobiol Aging 55:159-166|
Showing the most recent 10 out of 106 publications